SYNEOS HEALTH UK LIMITED

The global clinical trials market is projected to grow from $55.2 billion in 2023 to $83.16 billion by 2030, at a CAGR of 6.03%. Growth is driven by technological advancements, precision medicine, and the increasing burden of diseases. North America leads due to high R&D expenditure and robust regulatory frameworks. Oncology dominates the indication segment, with Phase III trials holding the largest market share. Interventional studies lead by study material, fueled by the demand for improved diagnostics and vaccines.

The global clinical trials market is projected to grow from US$55.20 billion in 2023 to US$83.16 billion by 2030, at a CAGR of 6.03%. Growth is driven by technological advancements, precision medicine, and the increasing burden of diseases. North America leads due to high R&D expenditure and a robust regulatory framework. Phase III trials dominate, with oncology being the leading indication. Interventional studies are the most prevalent, fueled by the need for improved diagnostics and vaccines.

The Global Immuno-oncology Clinical Trials Market is projected to grow from USD 6.13 billion in 2023 to USD 12.87 billion by 2030, at a CAGR of 11.17%. The report analyzes market dynamics, competitive landscape, and profiles key vendors like AstraZeneca and BioNTech. It covers market segmentation by design, phase, indication, and regional prospects including North America, Asia-Pacific, and EMEA.

Private equity's role in healthcare is expanding, with significant investments in oncology and clinical research. OneOncology acquired two practices, extending its reach. A study highlights over 700 oncology clinics acquired by private equity from 2003 to 2022, raising concerns over care accessibility and affordability. Clinical research saw major deals, including Syneos Health's $7.1 billion buyout.